Computation-driven discovery of a next-generation canine monoclonal antibody for canine parvovirus therapy.

Abstract

Canine parvovirus (CPV) is a highly contagious and lethal pathogen that poses a major threat to canine health. Despite widespread vaccination efforts, CPV remains one of the primary causes of hemorrhagic enteritis and myocarditis. Also, current supportive therapy often fails to work well. Therefore, we urgently need to explore alternative or complementary therapeutic strategies. In this study, by integrating single B-cell sequencing technology with antigen-antibody structure prediction, we successfully screened the canine-derived monoclonal antibody (mAb) E9 against CPV. E9 exhibited high affinity and broad neutralizing activity in vitro, and achieved 80% therapeutic efficacy in vivo. This therapeutic effect highlights E9's great potential as a next-generation CPV biologic. In summary, our study offers a more efficient approach for acquiring neutralizing antibodies and provides a promising strategy for combating CPV.